my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
ActivBiotics, Inc. announced that its board of directors has appointed Steven C. Gilman, Ph.D. as chairman and chief executive officer. Dr. Gilman was previously the company's president and chief executive officer.
Dr. Gilman joined ActivBiotics in March 2004 as president and chief executive from Millennium Pharmaceuticals where he held a number of senior leadership roles including Vice President and General Manager, Inflammation, responsible for the inflammation business. Prior to Millennium, he was Group Director of the arthritis, pulmonary, immunology and antibacterial therapeutic areas at Pfizer Global Research and Development. He has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. He currently serves on the board of the Massachusetts Biotechnology Council and Nextcea, Inc., an early-stage private company. Dr. Gilman received his PhD and MS degrees in microbiology from Pennsylvania State University and his post-doctoral training at Scripps Clinic and Research Foundation.
Dr. Gilman succeeds Alan W. Dunton, M.D., who resigned as non-executive chairman earlier this year to become the CEO of Panacos Pharmaceuticals.
ActivBiotics' Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, announced the completion of the sale of ActivBiotics intellectual property assets for $3.5 million. The assets consisted of 1) Rifalazil, a Phase II antibiotic, 2) a library of novel rifamycin compounds, an ... more
ActivBiotics Set to Sell Proprietary Assets, Including Drug Product Candidates
Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, confirmed that the sale of ActivBiotics' proprietary assets will be carried out through a sealed bid at 12:00 PM on March 14, 2008. There has been substantial interest from various parties about different a ... more
ActivBiotics, Inc. and Metaphore Pharmaceuticals, Inc. announced that stockholder approval of the previously announced merger has been received and the merger is now complete. The merger creates a late-stage company with two clinical stage compounds and a robust pipeline of preclinical cand ... more
